Nov 10, 2025 • Benzinga
NEUTRAL
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( NASDAQ:VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Nov 07, 2025 • Benzinga
SOMEWHAT-BULLISH
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy - Vera Therapeutics ( NASDAQ:VERA )
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 ( p<0.0001 )
Nov 07, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with ...
Nov 07, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase ...
Nov 07, 2025 • Benzinga
SOMEWHAT-BULLISH
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( NASDAQ:VERA ) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase ...
Nov 06, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
BRISBANE, Calif., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy ( IgAN ) were presented as a featured late-breaking oral presentation during the opening plenary session of the ...